BR9916829A - Formulações aerossóis farmacêuticas contendo fluoroalcanos, budesonida e formoterol - Google Patents

Formulações aerossóis farmacêuticas contendo fluoroalcanos, budesonida e formoterol

Info

Publication number
BR9916829A
BR9916829A BR9916829-4A BR9916829A BR9916829A BR 9916829 A BR9916829 A BR 9916829A BR 9916829 A BR9916829 A BR 9916829A BR 9916829 A BR9916829 A BR 9916829A
Authority
BR
Brazil
Prior art keywords
budesonide
formoterol
formulations containing
aerosol formulations
pharmaceutical aerosol
Prior art date
Application number
BR9916829-4A
Other languages
English (en)
Inventor
Frank E Blondino
Michael Brucato
Maria W Buenafe
Kelly Cavanaugh
Original Assignee
Baker Norton Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22802357&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9916829(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Baker Norton Pharma filed Critical Baker Norton Pharma
Publication of BR9916829A publication Critical patent/BR9916829A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/124—Aerosols; Foams characterised by the propellant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C66/00—General aspects of processes or apparatus for joining preformed parts
    • B29C66/70—General aspects of processes or apparatus for joining preformed parts characterised by the composition, physical properties or the structure of the material of the parts to be joined; Joining with non-plastics material
    • B29C66/71—General aspects of processes or apparatus for joining preformed parts characterised by the composition, physical properties or the structure of the material of the parts to be joined; Joining with non-plastics material characterised by the composition of the plastics material of the parts to be joined

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Patente de Invenção: "FORMULAçõES AEROSSóIS FARMACêUTICAS CONTENDO FLUOROALCANOS, BUDESONIDA E FORMOTEROL". A invenção refere-se a uma formulação aerossol de solução adaptada para uso em um recipiente aerossol pressurizado. A formulação aerossol é formulada a partir de uma composição contendo Budesonida, Formoterol, pelo menos um propelente de fluoroalcano, e um co-solvente presente em uma quantidade que dissolva ou solubilize o Budesonida e Formoteroi na mistura de co-solvente e propelente.
BR9916829-4A 1998-12-18 1999-12-17 Formulações aerossóis farmacêuticas contendo fluoroalcanos, budesonida e formoterol BR9916829A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/215,280 US6004537A (en) 1998-12-18 1998-12-18 Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol
PCT/US1999/030163 WO2000035441A2 (en) 1998-12-18 1999-12-17 Pharmaceutical aerosol formulations containing fluoroalkanes, budesonide and formoterol

Publications (1)

Publication Number Publication Date
BR9916829A true BR9916829A (pt) 2001-10-23

Family

ID=22802357

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9916829-4A BR9916829A (pt) 1998-12-18 1999-12-17 Formulações aerossóis farmacêuticas contendo fluoroalcanos, budesonida e formoterol

Country Status (12)

Country Link
US (1) US6004537A (pt)
EP (1) EP1140059A2 (pt)
JP (1) JP4921639B2 (pt)
AR (1) AR021922A1 (pt)
AU (1) AU776257B2 (pt)
BR (1) BR9916829A (pt)
CA (1) CA2355932C (pt)
CZ (1) CZ20012216A3 (pt)
HU (1) HUP0200014A3 (pt)
PL (1) PL348809A1 (pt)
TW (1) TW574038B (pt)
WO (1) WO2000035441A2 (pt)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4003272A1 (de) * 1990-02-03 1991-08-08 Boehringer Ingelheim Kg Neue treibgasmischungen und ihre verwendung in arzneimittelzubereitungen
EP0835098B1 (de) * 1995-06-27 2002-09-04 Boehringer Ingelheim Pharma KG Neue stabile arzneimittelzubereitung zur erzeugung treibgasfreier aerosole
GB9616237D0 (en) 1996-08-01 1996-09-11 Norton Healthcare Ltd Aerosol formulations
US20010031244A1 (en) * 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
SE9703407D0 (sv) 1997-09-19 1997-09-19 Astra Ab New use
SE9802073D0 (sv) 1998-06-11 1998-06-11 Astra Ab New use
US6451285B2 (en) * 1998-06-19 2002-09-17 Baker Norton Pharmaceuticals, Inc. Suspension aerosol formulations containing formoterol fumarate and a fluoroalkane propellant
IT1303788B1 (it) * 1998-11-25 2001-02-23 Chiesi Farma Spa Formulazioni di aerosol medicinali.
DZ2947A1 (fr) * 1998-11-25 2004-03-15 Chiesi Farma Spa Inhalateur à compteur de dose sous pression.
US6290930B1 (en) * 1998-12-18 2001-09-18 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes and budesonide
US6315985B1 (en) * 1999-06-18 2001-11-13 3M Innovative Properties Company C-17/21 OH 20-ketosteroid solution aerosol products with enhanced chemical stability
IT1313553B1 (it) * 1999-07-23 2002-09-09 Chiesi Farma Spa Formulazioni ottimizzate costituite da soluzioni di steroidi dasomministrare per inalazione.
ES2274803T3 (es) * 1999-09-11 2007-06-01 Glaxo Group Limited Formulacion farmaceutica de propionato de fluticasona.
DE60019167T2 (de) * 1999-12-24 2006-05-11 Glaxo Group Ltd., Greenford Pharmazeutische aerosol formulierung enthaltend salmeterol und fluticason
IT1317720B1 (it) * 2000-01-07 2003-07-15 Chiesi Farma Spa Dispositivo per la somministrazione di aerosol dosati pressurizzati inpropellenti idrofluoroalcani.
IT1317846B1 (it) 2000-02-22 2003-07-15 Chiesi Farma Spa Formulazioni contenenti un farmaco anticolinergico per il trattamentodella broncopneumopatia cronica ostruttiva.
GB0009584D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Pharmaceutical compositions
IT1318514B1 (it) * 2000-05-12 2003-08-27 Chiesi Farma Spa Formulazioni contenenti un farmaco glucocorticosteroide per iltrattamento di patologie broncopolmonari.
US20060257324A1 (en) * 2000-05-22 2006-11-16 Chiesi Farmaceutici S.P.A. Pharmaceutical solution formulations for pressurised metered dose inhalers
BR0015884A (pt) * 2000-05-22 2003-07-08 Chiesi Farma Spa Formulações de soluções farmacêuticas estáveis para inaladores de dose medida pressurizados
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
US20030055026A1 (en) * 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
DK1273292T3 (da) * 2001-07-02 2004-10-04 Chiesi Farma Spa Optimeret tobramycinformulering til aerosoldannelse
SE0200312D0 (sv) 2002-02-01 2002-02-01 Astrazeneca Ab Novel composition
EP3384931B1 (en) * 2002-03-01 2019-07-24 Chiesi Farmaceutici S.p.A. Formoterol superfine formulation
GB0207899D0 (en) * 2002-04-05 2002-05-15 3M Innovative Properties Co Formoterol and cielesonide aerosol formulations
MXPA05002248A (es) * 2002-08-27 2005-06-08 Schering Corp Procedimiento para producir formulaciones de inhalador de dosis medida.
SE0203376D0 (sv) * 2002-11-15 2002-11-15 Astrazeneca Ab New process
TWI359675B (en) * 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
AR041873A1 (es) * 2003-10-30 2005-06-01 Pablo Cassara Srl Lab Una formulacion farmaceutica en aerosol adecuada para la inhalacion oral o nasal que contienen glucocorticoides en solucion estable al almacenamiento; un metodo para estabilzar formulaciones y uso de un agente estabilizante
EP1595531A1 (en) 2004-05-13 2005-11-16 CHIESI FARMACEUTICI S.p.A. Stable pharmaceutical solution formulations for pressurized metered dose inhalers
TWI482748B (zh) * 2005-06-24 2015-05-01 Honeywell Int Inc 含有經氟取代之烯烴之組合物
GB0604141D0 (en) * 2006-03-01 2006-04-12 Arrow Int Ltd Nebulizer formulation
EP2117504A1 (en) * 2007-02-09 2009-11-18 Schering Corporation Stable pharmaceutical drug aerosols
US20100055045A1 (en) 2008-02-26 2010-03-04 William Gerhart Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
US20090215734A1 (en) * 2008-02-26 2009-08-27 Elevation Pharmaceuticals, Inc. Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
KR101748892B1 (ko) 2009-05-29 2017-06-19 펄 테라퓨틱스 인코포레이티드 지속형 무스카린 안타고니스트 및 지속형 ｂ₂아드레날린 수용체 아고니스트의 폐 전달용 조성물, 및 연관된 방법 및 시스템
US20120272951A1 (en) 2009-12-16 2012-11-01 3M Innovative Properties Company Formulations and methods for controlling mdi particle size delivery
TWI399202B (zh) 2011-03-17 2013-06-21 Intech Biopharm Ltd 製備用於治療呼吸道疾病之定量噴霧吸入劑的製程方法
CN102362860A (zh) * 2011-10-27 2012-02-29 江阴长风医药科技有限公司 以氢氟烷烃为抛射剂的布地奈德和福莫特罗气雾剂制剂
ITMI20130571A1 (it) 2013-04-10 2014-10-11 Zambon Spa Composizione farmaceutica contenente budesonide e formoterolo
ES2892673T3 (es) 2016-09-19 2022-02-04 Mexichem Fluor Sa De Cv Composición farmacéutica que comprende glicopirrolato
JP7268965B2 (ja) * 2018-06-05 2023-05-08 アース製薬株式会社 定量噴射型エアゾール製品および消臭方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7708731A (nl) * 1976-08-13 1978-02-15 Montedison Spa Werkwijze voor de bereiding van nieuwe drijf- middelsamenstellingen voor aerosolen.
US5225183A (en) * 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
JP2769925B2 (ja) * 1990-10-18 1998-06-25 ミネソタ マイニング アンド マニュファクチャリング カンパニー ベクロメタゾン１７，２１ジプロピオネートを含んで成るエアロゾル製剤
MX9203481A (es) * 1990-10-18 1992-07-01 Minnesota Mining & Mfg Formulaciones.
US5190029A (en) * 1991-02-14 1993-03-02 Virginia Commonwealth University Formulation for delivery of drugs by metered dose inhalers with reduced or no chlorofluorocarbon content
AU2178392A (en) * 1991-06-12 1993-01-12 Minnesota Mining And Manufacturing Company Albuterol sulfate suspension aerosol formulations
DE4123663A1 (de) * 1991-07-17 1993-01-21 Schwabe Willmar Gmbh & Co Aerosol-zubereitung und verwendung eines treibmittels dafuer
US5674471A (en) * 1991-12-12 1997-10-07 Glaxo Group Limited Aerosol formulations containing P134a and salbutamol
US5653962A (en) * 1991-12-12 1997-08-05 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicaments
HU0004452D0 (pt) * 1991-12-18 2001-01-29 Astra Ab
ATE137666T1 (de) * 1991-12-31 1996-05-15 Hoechst Ag Medizinische aerosolformulierung
GB9612297D0 (en) * 1996-06-11 1996-08-14 Minnesota Mining & Mfg Medicinal aerosol formulations
GB9616237D0 (en) * 1996-08-01 1996-09-11 Norton Healthcare Ltd Aerosol formulations
SE9603669D0 (sv) * 1996-10-08 1996-10-08 Astra Ab New combination
SE9703407D0 (sv) * 1997-09-19 1997-09-19 Astra Ab New use
SE9802073D0 (sv) * 1998-06-11 1998-06-11 Astra Ab New use

Also Published As

Publication number Publication date
CZ20012216A3 (cs) 2002-04-17
AU2194900A (en) 2000-07-03
PL348809A1 (en) 2002-06-17
EP1140059A2 (en) 2001-10-10
CA2355932A1 (en) 2000-06-22
HUP0200014A2 (hu) 2002-06-29
CA2355932C (en) 2009-06-23
TW574038B (en) 2004-02-01
AU776257B2 (en) 2004-09-02
US6004537A (en) 1999-12-21
WO2000035441A3 (en) 2000-10-26
HUP0200014A3 (en) 2005-06-28
JP2002532418A (ja) 2002-10-02
WO2000035441A2 (en) 2000-06-22
JP4921639B2 (ja) 2012-04-25
AR021922A1 (es) 2002-09-04

Similar Documents

Publication Publication Date Title
BR9916829A (pt) Formulações aerossóis farmacêuticas contendo fluoroalcanos, budesonida e formoterol
BR9916830A (pt) Formulações aerossóis farmacêuticas contendo fluoroalcanos e budesonide
AR013614A1 (es) Nueva composicion que comprende una combinacion de esteroides, un kit que la contiene, el uso de la misma, el uso de dicho kit de formoterol y debudesonida en la fabricacion de un medicamento
PT983058E (pt) Produtos medicinais para aerossois
BR9916865A (pt) Composição farmacêutica em aerossol contendohfa 227 e hfa 134a
PT1140019E (pt) Formulacoes em aerosol para aplicacao bucal e pulmonar
ES2064160T3 (es) Formulacion de aerosol que comprende 17,21-dipropionato de beclometasona.
BR0014441A (pt) Composições que apresentam estabilidade aperfeiçoada
DK0656207T3 (da) Aerosolformuleringer uden chlorfluorcarbonforbindelser
ES2112988T3 (es) Formulaciones de aerosol que contienen dipropionato de beclometasona sin agentes tensioactivos.
BR9810729A (pt) Composição farmacêutica para compostos lipofìlicos ácidos disposta como uma formulação auto-emulsionante
BR0112322A (pt) Nova formulação aerossol contendo uma molécula fluorada polar
BR9914932A (pt) Processo para a manufatura de uma composição de isotretinoìna, composição de isotretinoìna micronizada, forma de dosagem unitária para administração enteral e composição farmacêutica na forma de dosagem unitária
IT1320176B1 (it) Dispersioni solide di principi attivi nitrati.
BR9712125A (pt) Formulação farmaucêutica em aerosol, uso de uma mistura, produto farmacêutico, e, processo de administração de budesonida a um paciente
ES2134634T3 (es) Composiciones farmaceuticas y dispositivos para su administracion.
CL2004001325A1 (es) Una composicion farmaceutica de aerosol que comprende cilesonida solubilizada en un propelente hidrofluorocarbono y un co-solvente, de preferencia etanol, util como antiinflamatorio de las vias aereas.
HUP0002533A2 (hu) Asztmaellenes gyógyszerhatóanyagok új kombinációja
DK0853476T3 (da) Nimesulidholdigt farmaceutisk præparat til topisk anvendelse
BRPI0411734A (pt) composições farmacêuticas tipo adesivo, composições farmacêuticas aplicáveis oralmente e processo para a sìntese de misturas de e/z-isÈmeros de norelgestromina

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DA INT. CL.: A61K 31/165; A61K 31/58; A61K 9/12; A61K 47/10

Ipc: A61K 31/165 (2008.04), A61K 31/58 (2008.04), A61K

B25D Requested change of name of applicant approved

Owner name: IVAX LABORATORIES, INC. (US)

Free format text: ALTERADO DE: BAKER NORTON PHARMACEUTICALS, INC.

B25D Requested change of name of applicant approved

Owner name: IVAX RESEARCH, INC. (US)

Free format text: ALTERADO DE: IVAX LABORATORIES, INC.

B25C Requirement related to requested transfer of rights

Owner name: IVAX RESEARCH, INC. (US)

Free format text: A FIM DE ATENDER AO TERCEIRO ATO SOLICITADO ATRAVES DA PETICAO NO 020080134491/RJ DE 23/10/2008, QUEIRA COMPLEMENTAR O VALOR RECOLHIDO, UMA VEZ QUE TRATA-SE DE UMA TRANSFERENCIA POR FUSAO, E NAO DE UMA ALTERACAO DE NOME.

B25B Requested transfer of rights rejected

Owner name: IVAX RESEARCH, INC. (US)

Free format text: INDEFERIDO O PEDIDO DE TRANSFERENCIA, POR FALTA DE CUMPRIMENTO DA EXIGENCIA, PUBLICADA NA RPI 1994DE 24/03/2009.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8, 11, 13 E 25 DA LPI

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.